Larimar Therapeutics (LRMR) News Today

Larimar Therapeutics, Inc. (NASDAQ:LRMR) saw mixed news impacting its shares today. The company delivered better‐than‐expected quarterly results and strengthened its cash position, but also announced a sizable equity offering and faced lower price targets.

• Positive Sentiment: Q2 2025 earnings beat expectations, reporting EPS of –$0.41 vs. consensus of –$0.47. View Press Release
• Positive Sentiment: Pro forma cash position of $203.6 million after raising $65.1 million in July’s public offering. Second Quarter 2025 Financial Results
• Neutral Sentiment: Listed among “3 Best Stocks to Buy Now” in an MSN Markets roundup of top analyst picks. 3 Best Stocks to Buy Now
• Neutral Sentiment: Advances its Nomlabofusp program amid ongoing financial losses, underscoring pipeline progress. Nomlabofusp Program Update
• Neutral Sentiment: Wedbush lowered its FY2028 EPS estimate to $0.11 (from $0.18) but maintained an “Outperform” rating and $15 price objective. Wedbush EPS Revision
• Negative Sentiment: Announced a $64.4 million stock offering, raising dilution concerns. Stock Offering Announcement
• Negative Sentiment: Citizens JMP cut its price target from $22 to $18, signaling a more cautious near‐term outlook. Price Target Lowered

Overall, strong operational results and a solid cash runway have been counterbalanced by share dilution and reduced analyst targets, pressuring LRMR shares today.